Condition: Triple Negative Breast Cancer · Diffuse Large B Cell Lymphoma · Follicular Lymphoma · Sponsor: OncoNano Medicine, Inc.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.
This description comes directly from the study's public registry record.
Trials@OncoNanoMed.com · (682) 285-1411 · trials@onconanomed.com
Always discuss trial participation with your own doctor first.
| California Research Institute | Los Angeles, California, United States | Active Not Recruiting |
| BRCR Global | Tamarac, Florida, United States | Withdrawn |
| Gabrail Cancer Center Research | Canton, Ohio, United States | Completed |
| Ohio State University | Columbus, Ohio, United States | Completed |
| Allegheny Health Network | Pittsburgh, Pennsylvania, United States | Completed |
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Completed |
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Completed |
| MD Anderson Cancer Center | Houston, Texas, United States | Active Not Recruiting |
| Virginia Cancer Specialists, PC | Fairfax, Virginia, United States | Completed |
| St Vincent's Hospital | Darlinghurst, New South Wales, Australia | Recruiting |
| Cancer Care Wollongong | Wollongong, New South Wales, Australia | Recruiting |
| University of the Sunshine Coast Clinical Trials | Buderim, Queensland, Australia | Recruiting |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06022029